Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M

Aurinia Pharmaceuticals Inc.

2023-Q1 EPS reported -$0.18 revenue$34,409,000

Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.
Raised FY 2023 LUPKYNIS net product revenue guidance to $135-155M, from prior $120-140M.
1,731 patients on LUPKYNIS therapy at March 31, 2023, up from 1,071 a year earlier; 466 PSFs added in Q1.
New method-of-use patent issued; NICE positive recommendation for LUPKYNIS in UK; Swiss regulatory approval received.
Cash and short-term investments $361.5M at quarter end vs $389.4M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported first quarter ended March 31, 2023 results: revenue $34.4 million, net income $26.2 million or $0.18 net loss per common share, EPS $0.18 net loss per common share. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $34.4 million
Net income: $26.2 million or $0.18 net loss per common share
EPS: $0.18 net loss per common share
Guidance: raised
Result: reported results

Exact text from the filing

as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.